Abstract 530P
Background
Recent evidence have showed that high level of systemic inflammation is associated with poor survival in patients with malignancy by promoting cell proliferation. Inflammation-based serum biomarkers including C Reactive Protein (CRP), Albumin (ALB) and CRP/ALB ratio have been showed to have prognostic value in patients with Small Cell Lung Cancer (SCLC). C-reactive protein (CRP) is a nonspecific serum marker of acute-phase inflammatory response. Studies have hypothesized that High CRP is a surrogate marker of tissue inflammation secondary to tumor growth. Albumin is both an inflammatory and nutritional marker. They are readily available and cost-effective tests that are potential prognostic biomarkers and therapeutic targets. Prognostic biomarkers help to optimize therapy decisions, as they provide information on the likelihood of response to a given chemotherapeutic regimen.
Methods
The databases of PubMed, Cochrane, and Google Scholar were systematically searched until July 2019. Associations between CRP, ALB and CRP/ALB ratio and overall survival (OS) were investigated by pooling hazard ratio (HR) and 95% confidence interval (CI).
Results
A total of 13 studies comprising of 2,034 patients were included. The results showed that only High CRP (HR 1.36, CI 95% 1.01, 1.82 p = 0.04) and High CRP/ALB (HR 1.38, CI 9%% 1.15, 1.64 p = 0.0004) ratio are significantly associated with overall survival. Albumin has no statistical association with OS.
Conclusions
High CRP and CRP/ALB ratio are independent prognostic biomarkers in patients with SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract